Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Healthcare Without Walls: Revolution or Risk?

Join the Cambridge Wireless HeatlhTech SIG for a half-day event ( 13:30 – 17:30) exploring the transformative shift from traditional hospital-centred care to decentralised healthcare models.

As community hospitals, home-based care, distributed clinical trials and patient assessments redefine the landscape, industry experts will convene to tackle pressing medtech challenges. Keynote speakers and panel discussions will delve into overcoming infrastructure, accessibility and equity barriers, leveraging innovative technologies and data-driven solutions.

Early In Vitro Preclinical Cardiovascular Safety Assessment for Smarter Drug Discovery

Cardiovascular safety is a leading cause of drug attrition and often emerges too late, when the costs of failure are at their highest. For drug discovery scientists, identifying cardiac liabilities early in the development pipeline is not only a scientific imperative but also a strategic necessity. Early detection enables informed decision-making, more efficient use of resources, and the opportunity to refine or deprioritise candidates before significant investment in preclinical or clinical development.

Open Webinar: The Double-Edged Role of Extracellular Vesicles in Alzheimer's Disease

Time: 10:00 AM EDT | Format: Online | Free Registration

Extracellular vesicles (EVs), lipid bilayer-enclosed particles secreted by most cell types, are gaining increasing attention for their dualistic roles in neurodegenerative disorders. In Alzheimer's disease (AD), EVs function as both messengers of toxicity and protectors of neuronal integrity, making them critical yet complex components in disease progression and potential therapy.

 

'Our Critical Decade for Climate Action’ conference at UEA

To mark the 25th anniversary of the Tyndall Centre for Climate Change Research, the University of East Anglia (UEA), which leads the Tyndall Centre, is holding its largest ever climate conference. Many of the brightest minds on climate change are attending to discuss the ‘critical decade for climate action’ ahead of us and to discuss what university research needs to happen in the next five years that is truly useful for climate change action.

Introducing the o2h Peptide Guarantee: Get peptide delivered in 2 weeks. If delayed, it's on us.

Timely access to high-quality peptides is essential in drug discovery, especially for screening, structure-activity relationship (SAR) studies, and early-stage preclinical research. Any delay in peptide synthesis can slow down critical experiments, affect project timelines, and limit the ability to make rapid decisions in lead optimisation.

Postdoctoral Fellow in computational modelling of NeuroImmune Mechanisms of Neurodegeneration (Open Targets)

Your role

As a Postdoctoral Fellow on the NeuroImmune Open Targets project, you will develop and apply integrative computational pipelines to dissect immune-cell phenotypes and cell–cell interactions across Alzheimer’s, Parkinson’s, and Amyotrophic lateral sclerosis patient tissues and matched induced pluripotent stem cells models.

Your group

Saez-Rodriguez Research Group in collaboration with Open-Targets

Your supervisor

Julio Saez-Rodriguez

You will

o2h ChaiTime Webinar: Trump’s Most-Favored-Nation Drug Pricing is Rewiring Traditional R&D Model

Join us for the upcoming o2h ChaiTime Webinar, where our expert panellists will discuss how MFN pricing could reshape R&D strategies, operations, decision-making for biotech and pharma. 

The biopharma landscape is shifting fast, driven by evolving pricing policies, geopolitical trade tensions, and mounting pressure to optimise R&D investment. With the recent push toward nation-based drug pricing, global companies are being forced to rethink not just pricing models, but where and how they innovate. 

Subscribe to